<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: There are various approaches to the treatment of <z:e sem="disease" ids="C0037286" disease_type="Neoplastic Process" abbrv="">cutaneous tumors</z:e>; one of them is treatment with <z:chebi fb="0" ids="36704">imiquimod</z:chebi>, a synthetic toll-like receptor <z:chebi fb="4" ids="48705">agonist</z:chebi> with a low molecular weight that offers a topical, noninvasive, and non-surgical therapeutic option </plain></SENT>
<SENT sid="1" pm="."><plain>The main objective of our study was to provide data on 89 patients who used a 5% <z:chebi fb="0" ids="36704">imiquimod</z:chebi> cream for the treatment of <z:e sem="disease" ids="C0037286" disease_type="Neoplastic Process" abbrv="">cutaneous tumors</z:e> at the Cutaneous <z:hpo ids='HP_0002664'>Oncology</z:hpo> Group of the Dermatology Department of Hospital das Clinicas from 2003 to 2008 </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIALS AND METHODS: Here, we present our experience in the treatment of 123 cutaneous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> of various types, including <z:hpo ids='HP_0002671'>basal cell carcinoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e>), <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo> (<z:mp ids='MP_0004207'>SCC</z:mp>), <z:e sem="disease" ids="C0006079" disease_type="Neoplastic Process" abbrv="">Bowen's disease</z:e>, <z:e sem="disease" ids="C0154089" disease_type="Neoplastic Process" abbrv="">erythroplasia of Queyrat</z:e>, <z:e sem="disease" ids="C0029401" disease_type="Disease or Syndrome" abbrv="">Paget's disease</z:e>, and <z:mp ids='MP_0002732'>trichoepithelioma</z:mp>, with 5% <z:chebi fb="0" ids="36704">imiquimod</z:chebi> cream from 2003 to 2008 in the Cutaneous <z:hpo ids='HP_0002664'>Oncology</z:hpo> Group of the Dermatology Department of Hospital das Clinicas </plain></SENT>
<SENT sid="3" pm="."><plain>Patients were divided into two separate groups according to their diagnosis and comorbidities; these comorbidities included <z:e sem="disease" ids="C0014522" disease_type="Neoplastic Process" abbrv="EV|EVER">epidermodysplasia verruciformis</z:e>, <z:e sem="disease" ids="C0043346" disease_type="Neoplastic Process" abbrv="">xeroderma pigmentosum</z:e>, <z:hpo ids='HP_0001022'>albinism</z:hpo>, <z:hpo ids='HP_0002671'>basal cell nevus</z:hpo> syndrome, Brooke-Spiegler syndrome, HIV, <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and kidney transplantation </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment duration, response to <z:chebi fb="0" ids="36704">imiquimod</z:chebi>, follow-up, recurrence, and local and systemic reactions associated with use of the drug were analyzed </plain></SENT>
<SENT sid="5" pm="."><plain>Epidemiological data were obtained and cure rates were calculated </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The ratio of women to men was 1.28:1, and the mean age was 63.1 years </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumors</z:e> were located mainly on the face, back, trunk, and legs </plain></SENT>
<SENT sid="8" pm="."><plain>For patients with comorbidities, the overall cure rate was 38% </plain></SENT>
<SENT sid="9" pm="."><plain>These specific patients demonstrated cure rates of 83.5% for superficial <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> and 50% for <z:e sem="disease" ids="C0006079" disease_type="Neoplastic Process" abbrv="">Bowen's disease</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Aggressive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> and superficial and nodular <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> did not present a good response to treatment </plain></SENT>
<SENT sid="11" pm="."><plain><z:mp ids='MP_0002732'>Trichoepitheliomas</z:mp> and nodular <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> showed a partial response, and <z:e sem="disease" ids="C0154089" disease_type="Neoplastic Process" abbrv="">erythroplasia of Queyrat</z:e> showed a complete response </plain></SENT>
<SENT sid="12" pm="."><plain>For patients without comorbidities, the overall cure rate was 73% </plain></SENT>
<SENT sid="13" pm="."><plain>For these patients, the cure rates were 85.7% for superficial and nodular <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e>, 88% for superficial <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e>, 57% for <z:e sem="disease" ids="C0006079" disease_type="Neoplastic Process" abbrv="">Bowen's disease</z:e>, 50% for nodular <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e>, and 50% for aggressive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>One <z:mp ids='MP_0004207'>SCC</z:mp> lesion demonstrated a complete response, and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> caused by <z:e sem="disease" ids="C0029401" disease_type="Disease or Syndrome" abbrv="">Paget's disease</z:e> and <z:e sem="disease" ids="C0154089" disease_type="Neoplastic Process" abbrv="">erythroplasia of Queyrat</z:e> presented a partial response </plain></SENT>
<SENT sid="15" pm="."><plain>None of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> considered as clinically cured recurred </plain></SENT>
<SENT sid="16" pm="."><plain>Thirty-seven lesions demonstrated no response to <z:chebi fb="0" ids="36704">imiquimod</z:chebi> </plain></SENT>
<SENT sid="17" pm="."><plain>Having a cutaneous comorbidity, high-risk <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> such as mixed aggressive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> (sclerodermiform or micronodular), nodular <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e>, or <z:e sem="disease" ids="C0006079" disease_type="Neoplastic Process" abbrv="">Bowen's disease</z:e>, and presenting no local reaction to <z:chebi fb="0" ids="36704">imiquimod</z:chebi> were considered as risk factors for a worse prognosis </plain></SENT>
<SENT sid="18" pm="."><plain>We demonstrate that patients with no response to <z:chebi fb="0" ids="36704">imiquimod</z:chebi>, even when they demonstrated no local reaction, can undergo another cycle of six weeks of <z:chebi fb="0" ids="36704">imiquimod</z:chebi> treatment and show a complete response </plain></SENT>
<SENT sid="19" pm="."><plain>The healing pattern led to good cosmetic outcomes, and the side effects were tolerable </plain></SENT>
<SENT sid="20" pm="."><plain>CONCLUSIONS: Our experience confirms <z:chebi fb="0" ids="36704">imiquimod</z:chebi> as an effective treatment option for several types of <z:e sem="disease" ids="C0037286" disease_type="Neoplastic Process" abbrv="">cutaneous tumors</z:e>, especially in patients without the cutaneous comorbidities cited above and with low-risk <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="21" pm="."><plain><z:chebi fb="0" ids="36704">Imiquimod</z:chebi> has a relatively low cost compared to other therapeutic options and can be delivered via ambulatory care to patients with surgery contraindications, and its side effects are tolerable </plain></SENT>
</text></document>